Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Shingrix Safety Information9
Contraindications:
Hypersensitivity to the active substances or to any component of the vaccine.
Special warnings and precautions:
As with all injectable vaccines:
- appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine;
- vaccination with Shingrix should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination;
- a protective immune response may not be elicited in all vaccinees.
Do not administer the vaccine intravascularly, intradermally or subcutaneously.
There are no data on the use of Shingrix in pregnant women and the effect on breast-fed infants of administration of Shingrix to their mothers has not been studied.
Adverse reactions:
- Very common (≥1/10): headache, gastrointestinal symptoms (including nausea, vomiting, diarrhoea and/or abdominal pain), myalgia, injection site reactions (such as pain, redness, swelling), fatigue, chills, fever.
- Common (≥1/100 to <1/10): injection site pruritus, malaise.
Please refer to the full prescribing information for further details.
